Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-4001C in Male Androgenetic Alopecia
NCT02280603Phase 2Completed
- Sponsor
- Dong-A ST
- Start
- Jan 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of DA-4001C in androgenetic alopecia (AGA) (2 arms), sponsored by Dong-A ST. Primary endpoint: Change from baseline in target area hair count per cm2 at 24 weeks. Started Jan 2014; status: completed.
02
Drugs
DA-4001C
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT02280603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02280603.